Montour Jessica, Lee Deborah, Snider Cathy, Jentes Emily S, Stauffer William
Texas Department of State Health Services, Austin, Texas.
Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, Georgia.
Am J Trop Med Hyg. 2017 Dec;97(6):1833-1835. doi: 10.4269/ajtmh.17-0337. Epub 2017 Aug 31.
The Centers for Disease Control and Prevention recommends that refugees at risk of infection be tested for microfilaria before treatment with ivermectin. We report observational results of this approach in African refugees in Texas. Daytime blood smears were performed for microfilaria on at-risk African refugees who arrived in Texas from July 1, 2014 through December 30, 2016. Clinics were asked if there were any adverse events reported among those who received ivermectin. Of the 422 persons screened, 346 (82%) were born in -endemic countries, with 332 (96%) of these being born in the Democratic Republic of Congo. No smears detected microfilaria, and all received presumptive ivermectin with no reports of significant adverse events. In this investigation, the prevalence of significant microfilarial load in sub-Saharan African refugees appeared to be low, and ivermectin treatment was safe and well tolerated.
美国疾病控制与预防中心建议，有感染风险的难民在接受伊维菌素治疗前应进行微丝蚴检测。我们报告了在得克萨斯州的非洲难民中采用这种方法的观察结果。对2014年7月1日至2016年12月30日抵达得克萨斯州的有感染风险的非洲难民进行了日间血涂片微丝蚴检测。询问诊所是否有接受伊维菌素治疗的患者报告任何不良事件。在422名接受筛查的人员中，346人（82%）出生于流行国家，其中332人（96%）出生于刚果民主共和国。未检测到微丝蚴涂片，所有患者均接受了推定的伊维菌素治疗，未报告重大不良事件。在这项调查中，撒哈拉以南非洲难民中微丝蚴高负荷的患病率似乎较低，伊维菌素治疗安全且耐受性良好。
